It’s possible to carve out an in between pricing. Kimmtrak is a good example. Right now only addresses half the uveal melanoma market. About 1k estimated in US and EU combined. It’s priced at 400k so doing 200M annualized. For a smaller company that’s not chump change. I’m not sure what happens price wise if they can expand so cutaneous melanoma. Probably still price at a premium depending on treatment effect bc will be gears towards late line post pd-1. Still though your point is well taken.
News 
Market Data 
Discover 
